Literature DB >> 22286862

How to recognize late-onset hypogonadism in men with sexual dysfunction.

Giovanni Corona1, Giulia Rastrelli, Linda Vignozzi, Edoardo Mannucci, Mario Maggi.   

Abstract

Late-onset hypogonadism (LOH) has been considered the most common form of male hypogonadism with a prevalence of approximately 1 in 100 men. Diagnosis of LOH should be made in symptomatic men with unequivocally low serum testosterone (T) levels. However, its clinical presentation is often insidious and difficult to recognize because it is characterized by nonspecific symptoms that make differential diagnosis with physiological ageing problematic. Sexual dysfunction is the most important determinant for medical consultation and the most specific symptom associated with low T. We therefore analysed a consecutive series of 1734 subjects who attended our unit for sexual dysfunction to investigate the associations between low T (different thresholds), sexual parameters, medical history data (delayed puberty, pituitary disease or cryptorchidism) and their physical exam results. Metabolic parameters, in particular waist circumference, display the greatest accuracy in detecting low T. We found that only the association of several symptoms and signs could significantly raise the clinical suspicion of low T. Structured inventories, which cluster together symptoms and signs of hypogonadism, can help clinicians suspect androgen deficiency. In particular, structured interviews, such as ANDROTEST, have been demonstrated to have a greater accuracy when compared to self reported questionnaires in detecting low T levels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22286862      PMCID: PMC3735094          DOI: 10.1038/aja.2011.138

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  33 in total

1.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

2.  Andropause and quality of life: findings from patient focus groups and clinical experts.

Authors:  Annoesjka Novák; Meryl Brod; Jolanda Elbers
Journal:  Maturitas       Date:  2002-12-10       Impact factor: 4.342

3.  Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers.

Authors:  Annalisa Tancredi; Jean-Yves Reginster; Florence Schleich; Georges Pire; Philippe Maassen; Francoise Luyckx; Jean-Jacques Legros
Journal:  Eur J Endocrinol       Date:  2004-09       Impact factor: 6.664

4.  Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling.

Authors:  J J Stĕpán; M Lachman; J Zvĕrina; V Pacovský; D J Baylink
Journal:  J Clin Endocrinol Metab       Date:  1989-09       Impact factor: 5.958

5.  A short clinical diagnostic self-rating scale for psychoneurotic patients. The Middlesex Hospital Questionnaire (M.H.Q.).

Authors:  S Crown; A H Crisp
Journal:  Br J Psychiatry       Date:  1966-09       Impact factor: 9.319

Review 6.  Update in testosterone therapy for men.

Authors:  Giovanni Corona; Giulia Rastrelli; Gianni Forti; Mario Maggi
Journal:  J Sex Med       Date:  2011-03       Impact factor: 3.802

7.  Validation of a screening questionnaire for androgen deficiency in aging males.

Authors:  J E Morley; E Charlton; P Patrick; F E Kaiser; P Cadeau; D McCready; H M Perry
Journal:  Metabolism       Date:  2000-09       Impact factor: 8.694

8.  Osteoporosis in men with idiopathic hypogonadotropic hypogonadism.

Authors:  J S Finkelstein; A Klibanski; R M Neer; S L Greenspan; D I Rosenthal; W F Crowley
Journal:  Ann Intern Med       Date:  1987-03       Impact factor: 25.391

9.  American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update.

Authors:  Steven M Petak; Howard R Nankin; Richard F Spark; Ronald S Swerdloff; Luis J Rodriguez-Rigau
Journal:  Endocr Pract       Date:  2002 Nov-Dec       Impact factor: 3.443

10.  Osteoporosis in men with hyperprolactinemic hypogonadism.

Authors:  S L Greenspan; R M Neer; E C Ridgway; A Klibanski
Journal:  Ann Intern Med       Date:  1986-06       Impact factor: 25.391

View more
  29 in total

Review 1.  Aging and sex hormones in males.

Authors:  Maria Chiara Decaroli; Vincenzo Rochira
Journal:  Virulence       Date:  2016-11-10       Impact factor: 5.882

Review 2.  Testosterone supplementation and body composition: results from a meta-analysis of observational studies.

Authors:  G Corona; V A Giagulli; E Maseroli; L Vignozzi; A Aversa; M Zitzmann; F Saad; E Mannucci; M Maggi
Journal:  J Endocrinol Invest       Date:  2016-05-30       Impact factor: 4.256

3.  The inter-relational effect of metabolic syndrome and sexual dysfunction on hypogonadism in type II diabetic men.

Authors:  N Amidu; W K B A Owiredu; C K Gyasi-Sarpong; H Alidu; B B Antuamwine; C Sarpong
Journal:  Int J Impot Res       Date:  2017-03-09       Impact factor: 2.896

4.  Reduction of calprotectin and phosphate during testosterone therapy in aging men: a randomized controlled trial.

Authors:  L Pedersen; L L Christensen; S M Pedersen; M Andersen
Journal:  J Endocrinol Invest       Date:  2016-12-20       Impact factor: 4.256

5.  How to define hypogonadism? Results from a population of men consulting for sexual dysfunction.

Authors:  G Rastrelli; G Corona; M Tarocchi; E Mannucci; M Maggi
Journal:  J Endocrinol Invest       Date:  2016-01-05       Impact factor: 4.256

6.  The SUBITO-DE study: sexual dysfunction in newly diagnosed type 2 diabetes male patients.

Authors:  G Corona; C B Giorda; D Cucinotta; P Guida; E Nada
Journal:  J Endocrinol Invest       Date:  2013-05-20       Impact factor: 4.256

Review 7.  Enclomiphene citrate for the treatment of secondary male hypogonadism.

Authors:  Katherine M Rodriguez; Alexander W Pastuszak; Larry I Lipshultz
Journal:  Expert Opin Pharmacother       Date:  2016-07-04       Impact factor: 3.889

8.  Gynecomastia in subjects with sexual dysfunction.

Authors:  E Maseroli; G Rastrelli; G Corona; V Boddi; A M L Amato; E Mannucci; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2014-02-11       Impact factor: 4.256

9.  Predictors and clinical consequences of starting androgen therapy in men with low testosterone: results from the SIAMO-NOI registry.

Authors:  G Rastrelli; L Giovannini; A E Calogero; D Gianfrilli; E Serra; A Pizzocaro; V A Giagulli; G Motta; G Vancieri; A Sperandio; S Andò; R Selice; G Luca; F Cocchiara; D Canale; M Maggi
Journal:  J Endocrinol Invest       Date:  2016-04-01       Impact factor: 4.256

Review 10.  The practical management of testosterone deficiency in men.

Authors:  Antonio Aversa; Abraham Morgentaler
Journal:  Nat Rev Urol       Date:  2015-10-13       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.